You are here

Neurocognitive Studies in Depersonalisation Disorder: A possible indication for rTMS?

Neurocognitive Studies in Depersonalisation Disorder: A possible indication of rTMS? 

You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Neurocognitve Studies in Depersonalisation Disorder: A possible indication of rTMS? 

Learning objectives: 

1.     To recognize the clinical features of depersonalization/derealization;

2.     Understand the possible neurophysiological basis for emotional numbing and its relationship to DP/DR;

3.     To be familiar with neuroimaging research in DP; 

4.     To understand the theoretical basis for rTMS as a possible treatment for DP/DR.

 

Date: Tuesday, December 3, 2019

Time: 3:00 pm EST, 12:00 pm PST

Format: LIVE

Cost: Members: $25 | Non-members $50 | Student Members FREE


Speakers: Anthony David, MD

 

Professor Anthony David, is Director, University College London Institute of Mental Health.
 

Professor David graduated in medicine from Glasgow University in 1980 and trained in neurology before entering psychiatry at the Maudsley Hospital, London.  He also has a Masters degree in Cognitive Neuropsychology.  He was an honorary consultant at the Maudsley from 1990-2018 and was awarded a personal chair from the Institute of Psychiatry, King’s College London in 1996. He was Vice Dean for Academic Psychiatry at the IoPPN in 2013-8.
 

Professor David has a wide and diverse range of research interests including schizophrenia, neuropsychiatry, medically unexplained syndromes and neuroimaging – both structural and functional.  He is especially interested in the concept of insight in schizophrenia and depersonalization disorder. Professor David is a Fellow of the Royal College of Physicians, the Royal College of Psychiatrists and the Academy of Medical Sciences.  He is a member of the Experimental Psychology Society and a founder member of both the British Neuropsychological Society and British Neuropsychiatry Association and was Chairman to the latter from 2004-7. He delivered the inaugural “King’s Lectures” in 2018 on the topic “Psychiatry, Science and Society”.


Acknowledgement of Financial and/or In-Kind Commercial Support

No financial or in-kind commercial support was received for this educational activity.

 

Satisfactory Completion 

Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.   

 

Physicians             

In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Disclosure of Conflict of Interest

The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco.  All of these relationships were treated as a conflict of interest, and have been resolved.  (C7 SCS 6.1-­6.2, 6.5)

 

All individuals in a position to control the content of CE are listed below.

 

Diversified mutual fund including stocks in pharmaceutical companies. :Stock Shareholder

 

First Name

Last Name

Commercial Interest:Relationship

Mo

Abdelghani

Takeda Pharmaceuticals:Consultant,Takeda Pharmaceuticals:Scientific/Medical Advisory Board Member,DM Practice Management:Other,Takeda Pharmaceuticals:Speakers Bureau,London TMS Centre:Owner and director,Dyad Medical Ltd:Other

Richard

Bermudes

American Psychiatric Association Publishing:Other

Anthony

David

NA

Bobbie

Fleming

NA

Steven

Harvey

Greenbrook TMS:Stock Shareholder

Sheryl

Morgan

NA

Bob

Sammons

NA

Questions? Email Certificate@AmedcoEmail.com

December 3rd, 2019 12:00 PM   through   1:00 PM
Phone: 845-392-3238
Email:
Event Fee
Grand Rounds Webinar
Grand Rounds Webinar Title Neurocognitive Studies in Depersonalisation Disorder: A possible indication of rTMS? 
Timezone
Time Zone Pacific
Event Thumbnail
Thumbnail

Help spread the word

Please help us and let your friends, colleagues and followers know about our page: Neurocognitive Studies in Depersonalisation Disorder: A possible indication for rTMS?


You can also share the below link in an email or on your website.
https://www.clinicaltmssociety.org/civicrm/event/info?id=57&reset=1